VMAT2：一种大脑单胺能神经元功能的动态调节剂，与滥用药物相互作用。
VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.
机构信息
Section on Molecular Neuroscience, Laboratory of Cellular and Molecular Regulation, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Ann N Y Acad Sci. 2011 Jan;1216:86-98. doi: 10.1111/j.1749-6632.2010.05906.x.
Abstract
The monoaminergic neuron, in particular the dopaminergic neuron, is central to mediating the hedonic and addictive properties of drugs of abuse. The effects of amphetamine (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, VMAT2. The potential role of DAT as a target for AMPH and COC has been reviewed extensively. Here, we present VMAT2 as a target that enables the rewarding and addictive actions of these drugs, based on imaging, neurochemical, biochemical, cell biological, genetic, and immunohistochemical evidence. The presence of VMAT2 in noradrenergic, serotoninergic, histaminergic, and potentially trace aminergic neurons invites consideration of a wider role for aminergic neurotransmission in AMPH and COC abuse and addiction.
摘要
单胺能神经元，尤其是多巴胺能神经元，是介导成瘾药物愉悦和成瘾特性的核心。例如，安非他命（AMPH）和可卡因（COC）的作用取决于通过对血浆膜转运体 DAT 或单胺储存的囊泡转运体 VMAT2 的影响，增加突触中多巴胺的能力。DAT 作为 AMPH 和 COC 的靶点的潜在作用已经被广泛研究。在这里，我们根据成像、神经化学、生物化学、细胞生物学、遗传学和免疫组织化学证据，将 VMAT2 作为这些药物产生奖赏和成瘾作用的靶点。VMAT2 存在于去甲肾上腺素能、血清素能、组胺能和潜在的微量胺能神经元中，这使得人们考虑到单胺能神经传递在 AMPH 和 COC 滥用和成瘾中的更广泛作用。
相似文献
1
VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.VMAT2：一种大脑单胺能神经元功能的动态调节剂，与滥用药物相互作用。
Ann N Y Acad Sci. 2011 Jan;1216:86-98. doi: 10.1111/j.1749-6632.2010.05906.x.
2
Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.在敲除小鼠中，囊泡单胺转运体 2（VMAT2）和多巴胺转运体（DAT）功能降低会影响多巴胺能系统的衰老。
Neuropharmacology. 2014 Jan;76 Pt A(0 0):146-55. doi: 10.1016/j.neuropharm.2013.07.031. Epub 2013 Aug 24.
3
Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.成年囊泡单胺转运体2（VMAT2）突变小鼠纹状体多巴胺神经传递的突触前控制
J Neurochem. 2003 May;85(4):898-910. doi: 10.1046/j.1471-4159.2003.01732.x.
4
Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour.多巴胺能、5-羟色胺能和去甲肾上腺素能神经传递的选择性基因破坏：对运动、情绪和成瘾行为的见解。
J Psychiatry Neurosci. 2016 Apr;41(3):169-81. doi: 10.1503/jpn.150028.
5
Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2.可卡因而非苯丙胺的短期治疗可提高大鼠脑囊泡单胺转运体2的密度。
J Neural Transm (Vienna). 2007;114(4):427-30. doi: 10.1007/s00702-006-0549-8. Epub 2006 Aug 8.
6
Coordinated expression of dopamine transporter and vesicular monoamine transporter in the primate striatum during development.在灵长类动物纹状体的发育过程中多巴胺转运体和囊泡单胺转运体的协调表达。
Synapse. 2013 Sep;67(9):580-5. doi: 10.1002/syn.21662. Epub 2013 Apr 18.
7
VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.帕金森病灵长类动物模型中的囊泡单胺转运体2与多巴胺能神经元损失
J Neurochem. 2008 Apr;105(1):78-90. doi: 10.1111/j.1471-4159.2007.05108.x. Epub 2007 Nov 5.
8
Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration.反复给予苯丙胺后大鼠中脑多巴胺转运体和囊泡单胺转运体2 mRNA的表达
Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):137-48. doi: 10.1016/s0169-328x(97)00136-8.
9
Storage of neural histamine and histaminergic neurotransmission is VMAT2 dependent in the zebrafish.在斑马鱼中，神经组胺的储存和组胺能神经传递依赖于 VMAT2。
Sci Rep. 2017 Jun 8;7(1):3060. doi: 10.1038/s41598-017-02981-w.
10
Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.囊泡单胺转运体2（VMAT2）在单胺能神经元中的保护作用。
Mol Neurobiol. 2009 Apr;39(2):149-70. doi: 10.1007/s12035-009-8059-y. Epub 2009 Mar 4.
引用本文的文献
1
Role of Glial Trace Amine Associated Receptor 1 (TAAR1) and Microbiota in Schizophrenia.胶质细胞痕量胺相关受体1（TAAR1）和微生物群在精神分裂症中的作用
Neurochem Res. 2025 Aug 21;50(5):273. doi: 10.1007/s11064-025-04525-5.
2
Nigrostriatal dopaminergic neurotransmission and resilience to peripheral systemic risk factors for gait slowing upon transition to uneven surfaces in older adult.黑质纹状体多巴胺能神经传递与老年人在过渡到不平整表面时对步态减慢的外周系统性风险因素的恢复力。
Aging Brain. 2025 Jun 20;8:100143. doi: 10.1016/j.nbas.2025.100143. eCollection 2025.
3
Exploring α-Syn's Functions Through Ablation Models: Physiological and Pathological Implications.通过基因敲除模型探索α-突触核蛋白的功能：生理和病理意义
Cell Mol Neurobiol. 2025 May 19;45(1):44. doi: 10.1007/s10571-025-01560-2.
4
Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.平衡摇头丸和新型MDXX类似物作为自闭症谱系障碍新疗法的治疗效果与安全性
Psychedelic Med (New Rochelle). 2023 Sep 13;1(3):166-185. doi: 10.1089/psymed.2023.0023. eCollection 2023 Sep.
5
Serotonergic dysfunction in patients with impulse control disorders in Parkinson's disease.帕金森病冲动控制障碍患者的5-羟色胺能功能障碍
Brain. 2025 Jun 3;148(6):2108-2121. doi: 10.1093/brain/awaf087.
6
Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.基因、认知及其在甲基苯丙胺使用障碍中的相互作用
Biomolecules. 2025 Feb 19;15(2):306. doi: 10.3390/biom15020306.
7
Drug inhibition and substrate transport mechanisms of human VMAT2.人类囊泡单胺转运体2（VMAT2）的药物抑制作用及底物转运机制
Nat Commun. 2025 Jan 2;16(1):323. doi: 10.1038/s41467-024-55361-0.
8
The BE (2)-M17 neuroblastoma cell line: revealing its potential as a cellular model for Parkinson's disease.BE(2)-M17神经母细胞瘤细胞系：揭示其作为帕金森病细胞模型的潜力。
Front Cell Neurosci. 2024 Nov 26;18:1485414. doi: 10.3389/fncel.2024.1485414. eCollection 2024.
9
From Fundamentals to Innovation in Alzheimer's Disease: Molecular Findings and Revolutionary Therapies.从阿尔茨海默病的基础到创新：分子发现和革命性疗法。
Int J Mol Sci. 2024 Nov 16;25(22):12311. doi: 10.3390/ijms252212311.
10
Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats.克拉维酸和藏红花素对大鼠氟哌啶醇诱导的迟发性运动障碍的分子和行为神经保护作用
Mol Neurobiol. 2025 Apr;62(4):5156-5182. doi: 10.1007/s12035-024-04566-x. Epub 2024 Nov 9.
本文引用的文献
1
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.新型吡咯烷诺洛贝林类似物 UKCP-110[顺式-2,5-二-(2-苯乙基)-吡咯烷盐酸盐]抑制 VMAT2 功能、苯丙胺诱发的多巴胺释放和大鼠苯丙胺自我给药。
J Pharmacol Exp Ther. 2010 Dec;335(3):841-51. doi: 10.1124/jpet.110.172742. Epub 2010 Aug 30.
2
Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders.囊泡单胺转运体1（VMAT1/SLC18A1）中的基因变异与神经精神疾病
Methods Mol Biol. 2010;637:165-80. doi: 10.1007/978-1-60761-700-6_9.
3
An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes.精神分裂症易患基因上基因-功能相关性的综合基因组分析。
J Hum Genet. 2010 May;55(5):285-92. doi: 10.1038/jhg.2010.24. Epub 2010 Mar 26.
4
Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse.多巴胺转运体的调节：与精神兴奋剂滥用相关的方面。
Ann N Y Acad Sci. 2010 Feb;1187:316-40. doi: 10.1111/j.1749-6632.2009.05148.x.
5
Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.低剂量安非他命对囊泡单胺转运体结合的影响：人类正电子发射断层扫描 (+)[11C]DTBZ 研究。
Synapse. 2010 Jun;64(6):417-20. doi: 10.1002/syn.20743.
6
In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations.大鼠纹状体中[11C]二氢四苯嗪结合的体内研究：对多巴胺浓度的敏感性。
Nucl Med Biol. 2010 Jan;37(1):3-8. doi: 10.1016/j.nucmedbio.2009.08.013. Epub 2009 Oct 3.
7
Tetrabenazine.泰必利嗪。
Expert Opin Pharmacother. 2009 Dec;10(17):2883-96. doi: 10.1517/14656560903386292.
8
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.洛贝林通过抑制囊泡单胺转运体 2 抑制甲基苯丙胺诱导的多巴胺释放。
J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23.
9
Transitions in infant learning are modulated by dopamine in the amygdala.杏仁核中的多巴胺调节婴儿学习的转变。
Nat Neurosci. 2009 Nov;12(11):1367-9. doi: 10.1038/nn.2403. Epub 2009 Sep 27.
10
Treatment of hyperkinetic movement disorders.多动性运动障碍的治疗。
Lancet Neurol. 2009 Sep;8(9):844-56. doi: 10.1016/S1474-4422(09)70183-8.
Zotero 插件